BlackRock Fund Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

BlackRock Fund Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$110K	Buy	2,886 +97	+3%	+$3.36K	﹤0.01%	3586
2016 Q3	$101K	Buy	2,789 +2	+0.1%	+$75	﹤0.01%	3617
2016 Q2	$101K	Sell	2,787 -48	-2%	-$1.69K	﹤0.01%	3668
2016 Q1	$114K	Sell	2,835 -215	-7%	-$7.9K	﹤0.01%	3635
2015 Q4	$131K	Buy	3,050 +137	+5%	+$5.64K	﹤0.01%	3667
2015 Q3	$100K	Sell	2,913 -78	-3%	-$3.67K	﹤0.01%	3701
2015 Q2	$162K	Buy	+2,991	New	+$178K	﹤0.01%	3608

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock Fund Advisors's BCLI Position: Q4 2016 in Review

BlackRock Fund Advisors increased its BRAINSTORM CELL THERAPUTC (BCLI) stake by 3.5% in Q4 2016, buying an estimated $3.36K and bringing the position to 2,886 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.

BlackRock Fund Advisors first reported a position in BCLI in Q2 2015 and has held it in 7 quarters since. The position peaked at $162K in Q2 2015. 27 funds tracked by Wall St. Rank hold BCLI as of Q4 2016.

BlackRock Fund Advisors held 2,886 shares of BRAINSTORM CELL THERAPUTC worth $110K as of Q4 2016.
BlackRock Fund Advisors bought 97 BRAINSTORM CELL THERAPUTC shares in Q4 2016, an estimated $3.36K.
BRAINSTORM CELL THERAPUTC made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3586 holding.
BlackRock Fund Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's BRAINSTORM CELL THERAPUTC position peaked at $162K in Q2 2015.
27 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.